BLOOMINGTON, Ind. (Inside INdiana Business) — New Jersey-based Catalent Inc. (NYSE: CTLT) is continuing to grow its operation in Monroe County. The company says it is investing $50 million to install a third high-speed vial filling line at its Bloomington facility by April of next year.
Catalent provides delivery technologies, development, and manufacturing services for drugs, biologics, cell and gene therapies, and consumer health products.
When installation is complete, Catalent says the new line will give the company the ability to produce up to 80 million vials annually.
“The industry has seen an increased demand for vial filling of biologic drugs, which has been compounded by the accelerated development of vaccine and therapeutic candidates to address the COVID-19 pandemic,” Mike Riley, regional biologics president for North America at Catalent, said in a news release. “Catalent’s continued investment in this capacity will allow us to remain flexible and continue to support the growth of our customers’ programs.”
Catalent says the investment is its third at the Bloomington site over the last two years. The company recently completed a $14 million expansion in April.
The Bloomington facility is being utilized by Catalent as part of two partnerships involving potential COVID-19 vaccines. The company is partnering with Johnson & Johnson (NYSE: JNJ) and Massachusetts-based Moderna Inc. (Nasdaq: MRNA) to help manufacture their respective vaccine candidates.